Recombinant Cynomolgus SFRP2 Protein
Beta LifeScience
SKU/CAT #: BLK-01150P-100UG
Cynomolgus SFRP2 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.
Recombinant Cynomolgus SFRP2 Protein
Beta LifeScience
SKU/CAT #: BLK-01150P-100UG
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Product Overview
| Description | Recombinant Cynomolgus SFRP2 Protein is expressed from HEK293 with His tag at the C-Terminus.It contains Leu25-Cys295. |
| Purity | > 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC |
| Accession | G8F2Z7 |
| Target Symbol | SFRP2 |
| Species | Cynomolgus |
| Expression System | HEK293 |
| Tag | C-His |
| Expression Range | Leu25-Cys295 |
| Mol. Weight | The protein has a predicted MW of 32.16 kDa. Due to glycosylation, the protein migrates to 33-38 kDa based on Tris-Bis PAGE result. |
| Form | Lyophilized |
| Formulation | Lyophilized from 0.22um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
| Endotoxin | Less than 1EU per ug by the LAL method. |
| Storage | Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
| Shipping | Shipped at ambient temperature. |
| Gene Background | As biomarkers, DNA methylation is used to detect colorectal cancer (CRC) and make assessment of CRC prognosis. The published findings showed the association between the methylation of SFRP1, SFRP2, and WIF1, located in the Wnt signaling pathway, and the prognosis of CRC were not consistent. SFRP1, SFRP2, and WIF1 were frequently hypermethylated in CRC tumor tissues. It was apparent that the promoter hypermethylation of SFRP2 and co-hypermethylation of SFRP1 and SFRP2 might be considered as independent prognostic predictors for survival advantage of postoperative CRC patients. |
